Literature DB >> 21458889

[Immunosuppression in liver transplantation: renoprotective regimens].

M Trinidad Serrano Aulló1, Eduardo Parra Moncasi, Sara Lorente Pérez.   

Abstract

Both acute and chronic renal insufficiency are highly prevalent in liver transplant recipients. The etiology is multifactorial, with administration of nephrotoxic drugs playing a major role. Calcineurin inhibitors (CNI) (cyclosporin and tacrolimus) are the mainstay of immunosuppressive therapy in liver transplantation and produce acute and chronic nephrotoxicity. There are three main strategies to prevent renal injury: a) reduction of CNI to minimal levels accompanied by the use of an adjuvant drug such as azathioprine, mycophenolate mofetil or mammalian target of rapamycin (mTOR) inhibitors; b) complete withdrawal of CNI, using non-nephrotoxic drugs in their place; and c) use of protocols without CNI from the outset. The present article reviews these three strategies as well as their influence on renal function and on the results of liver transplantation.
Copyright © 2010 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21458889     DOI: 10.1016/j.gastrohep.2010.12.009

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  1 in total

Review 1.  Liver transplant immunosuppression during the covid-19 pandemic.

Authors:  Xavier Forns; Miquel Navasa
Journal:  Gastroenterol Hepatol       Date:  2020-06-12       Impact factor: 2.102

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.